<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00955539</url>
  </required_header>
  <id_info>
    <org_study_id>H-B-2009-057</org_study_id>
    <nct_id>NCT00955539</nct_id>
  </id_info>
  <brief_title>Viability and Cardiac Resynchronization Therapy</brief_title>
  <official_title>The Importance of Viability for Response to Cardiac Resynchronization Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lund University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      30% of heart failure patients that receive a device for cardiac resynchronization therapy
      fail to show clinical improvement. The reason for lack of response is still unclear but
      factors such as scar tissue in the heart musculature, inadequate lead placement,
      device-settings and the degree of dyssynchrony before implant seems to be important. In this
      study, these factors are further investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiac resynchronization therapy (CRT) is an established therapy for patients with severe
      heart failure, depressed left ventricular function and a wide QRS-complex. Large clinical
      trials have demonstrated unequivocal improvements in functional status, morbidity and
      mortality. However, 30 % of heart failure patients treated with a CRT-device do not benefit
      clinically. Several factors have been suggested to be important for the response to CRT such
      as mechanical dyssynchrony, presence of scar tissue in the myocardium, and
      device-optimization (among others). It is the purpose of this study to investigate the
      importance of these factors.

      100 patients with ischemic cardiomyopathy, eligible to CRT according to current guidelines,
      will be included. Patients are randomised to two arms. One group will have atrioventricular
      (AV)-optimization after implantation, the other AV -and interventricular (VV)-optimization.
      After 4 months patients are crossed-over to the other arm. Preimplantation patients are
      MR-scanned and low-dose dobutamine stress-echocardiography is performed. Furthermore patients
      will be examined by echocardiography and evaluation of clinical status

        1. Mechanical dyssynchrony can predict response to CRT. b. Measures of mechanical
           dyssynchrony is related to myocardial viability and conduction.

        2. Individual optimization based on conduction times will increase benefit to CRT. b. The
           effect of adding VV-optimization is related to myocardial viability.

        3. &gt; 30 % of non-viable tissue globally in the myocardium is predictive of lack of CRT-
           response. b. Non-viable tissue located in the area of the left ventricular lead is
           predictive of non-response.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responders:Echocardiographic:&gt;/= 10% increase in Left ventricular ejection fraction (LVEF) or &gt;/= 15 % reduction in left ventricular end-systolic volume (LVESV)</measure>
    <time_frame>4 and 8 months, ( follow up- 2 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>LVESV, LVEDV, Cardiac output (CO), Minnesota Living with Heart Failure Questionnaire (MLHFQ) ProBNP Others: t-wave modulation all-cause mortality, cardiac death, hospitalization</measure>
    <time_frame>4 and 8 months (follow-up after 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical: &gt;/= 25% increase in 6-min walk test or &gt;/= 1 reduction in NYHA-class</measure>
    <time_frame>4 and 8 months (follow-up 2 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Failure</condition>
  <condition>Ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>CRT group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CRT group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AV-optimization followed by AV- and VV-optimization</intervention_name>
    <description>Patients are AV-optimized the first 4 months,then AV- and VV-optimized the next 4 months.</description>
    <arm_group_label>CRT group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AV- and VV-optimization followed by AV-optimization only.</intervention_name>
    <description>Patients are AV- and VV-optimized the first 4 months,then AV-optimized the next 4 months.</description>
    <arm_group_label>CRT group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LVEF&lt;/= 35%, QRS-duration&gt;/= 120 ms, NYHA-class II- IV.

          -  Ischemic heart disease (&gt; 50% stenosis in 1 or more major epicardial coronary artery
             or prior PCI or CABG.)

          -  Optimal treatment ( beta-blocker, ACE-1 or ARB and spironolactone)

        Exclusion Criteria:

          -  Pregnancy

          -  Unstable angina pectoris

          -  Chronical atrial fibrillation

          -  Severe valvular disease

          -  Dementia or mental retardation

          -  Severe claustrophobia

          -  Acute myocardial infarction &lt; 3 months

          -  Severe health condition threatening short-term survival

          -  Severe kidney insufficiency, GFR &lt; 35 ml/min/1.73 m2

          -  Metal implants contraindicative of magnetic resonance scan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels Risum, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Gentofte, Department of cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Fritz Hansen, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Gentofte, department of cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter SÃ¸gaard, M.D., DMSc.</last_name>
    <role>Study Chair</role>
    <affiliation>Gentofte University Hospital, department of cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rasmus Borgquist, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Lund</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Niels E Bruun, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Gentofte University Hospital, department of cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Niels Risum, M.D.</last_name>
    <phone>+45 39978473</phone>
    <email>nieris01@geh.regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Fritz Hansen, M.D.</last_name>
    <phone>+45 39773977</phone>
    <email>THHAN@geh.regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gentofte University Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels Risum, M.D.</last_name>
      <phone>+45 39978473</phone>
      <email>nieris01@geh.regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Fritz Hansen, M.D.</last_name>
      <phone>+45 39773977</phone>
      <email>THHAN@geh.regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Niels Risum, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Lund</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rasmus Borgquist, MD, PhD</last_name>
      <phone>+46 70-4057350</phone>
      <email>rasmus.borgquist@med.lu.se</email>
    </contact>
    <investigator>
      <last_name>Rasmus Borgquist, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Bax JJ, Abraham T, Barold SS, Breithardt OA, Fung JW, Garrigue S, Gorcsan J 3rd, Hayes DL, Kass DA, Knuuti J, Leclercq C, Linde C, Mark DB, Monaghan MJ, Nihoyannopoulos P, Schalij MJ, Stellbrink C, Yu CM. Cardiac resynchronization therapy: Part 1--issues before device implantation. J Am Coll Cardiol. 2005 Dec 20;46(12):2153-67. Review.</citation>
    <PMID>16360042</PMID>
  </reference>
  <reference>
    <citation>Sogaard P, Egeblad H, Pedersen AK, Kim WY, Kristensen BO, Hansen PS, Mortensen PT. Sequential versus simultaneous biventricular resynchronization for severe heart failure: evaluation by tissue Doppler imaging. Circulation. 2002 Oct 15;106(16):2078-84.</citation>
    <PMID>12379577</PMID>
  </reference>
  <reference>
    <citation>Bleeker GB, Kaandorp TA, Lamb HJ, Boersma E, Steendijk P, de Roos A, van der Wall EE, Schalij MJ, Bax JJ. Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. Circulation. 2006 Feb 21;113(7):969-76. Epub 2006 Feb 13.</citation>
    <PMID>16476852</PMID>
  </reference>
  <reference>
    <citation>Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005 Apr 14;352(15):1539-49. Epub 2005 Mar 7.</citation>
    <PMID>15753115</PMID>
  </reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2009</study_first_submitted>
  <study_first_submitted_qc>August 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2009</study_first_posted>
  <last_update_submitted>October 4, 2011</last_update_submitted>
  <last_update_submitted_qc>October 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Niels Risum</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Cardiac resynchronization therapy</keyword>
  <keyword>Optimization</keyword>
  <keyword>Viability</keyword>
  <keyword>Mechanical dyssynchrony</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

